Fight against antibiotic crisis stymied by lack of R&D spend

A “concerning shortfall” in investment in costly late stage research and development (R&D) to battle antimicrobial resistance (AMR) means that future global health needs are unlikely to be met, according to a report by private sector coalition the AMR Industry Alliance.

The Alliance says this is despite its members stumping up US $1.6 billion for the purpose in 2018 and steps including continued investment in early R&D for products to tackle AMR such as antibiotics, vaccines and disease diagnostics.